Skip to main content
. 2021 Jun 18;6:84. doi: 10.1038/s41541-021-00345-0

Fig. 1. PfCSP mRNA-LNP induce potent functional antibodies and cytokine responses.

Fig. 1

PfCSP mRNA (TriLink) was encapsulated in three different LNP formulations. BALB/c were injected with 10 µg and 30 µg dose of PfCSP mRNA-LNPs in a 3 week interval prime:boost regimen (N = 5 per group). Serum and splenocytes were collected two weeks following the boost injection. a PfCSP antibody responses were determined by r-PfCSP titration ELISA and reported as the geometric mean (GM) with 95% confidence intervals (CI). b Avidity indices were calculated using a chaotrope-based avidity r-PfCSP titration ELISA and reported as the GM with 95% CI. c Functional activity of the antibodies was quantified by ILSDA using pooled mouse serum of each group. Inhibition was reported as the mean of assay replicates and calculated relative to the mean of sporozoite invasion in the absence of mouse serum. For d IFN-γ, e TNF-α, f IL-2, and g IL-12p70, splenocytes were incubated in the presence of a PfCSP overlapping 15-mer peptide pool. Cell culture supernatants were harvested after 48 h and cytokine concentrations quantified by MSD. Data are reported as the mean and standard error of the mean (SEM). All statistical analyses were performed using a Mann Whitney test (*p < 0.05; **p < 0.01).